Modified albumin-bilirubin grade and alpha-fetoprotein score for predicting prognosis of hepatocellular carcinoma patients undergoing conventional transarterial chemoembolization.

Journal: Oncology
Published Date: May 10, 2025

Abstract

BACKGROUND: Predicting post-treatment prognosis in hepatocellular carcinoma (HCC) patients undergoing conventional transarterial chemoembolization (cTACE) is challenging due to tumor heterogeneity. We here assessed the utility of the modified albumin‒bilirubin grade and α-fetoprotein (mALF) score for predicting the prognosis of cTACE-treated HCC patients.

Authors

  • Manabu Hayashi
  • Kazumichi Abe
  • Tatsuro Sugaya
  • Naoto Abe
  • Yosuke Takahata
  • Masashi Fujita
  • Hiromasa Ohira

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals